Chemistry:Samelisant

From HandWiki

Samelisant (INN; developmental code name SUVN-G3031) is an experimental wakefulness-promoting agent acting as a selective histamine H3 receptor inverse agonist which is under development for the treatment of narcolepsy.[1][2][3][4] It was also under development for the treatment of cognition disorders and Parkinson's disease, but no recent development has been reported for these indications.[1][3] As of June 2024, samelisant is in phase 2 clinical trials for the treatment of narcolepsy.[1][5]

See also

References

  1. ↑ 1.0 1.1 1.2 "Samelisant - Suven Life Sciences". 12 June 2024. https://adisinsight.springer.com/drugs/800032317. 
  2. ↑ "Revisiting Preclinical Observations of Several Histamine H3 Receptor Antagonists/Inverse Agonists in Cognitive Impairment, Anxiety, Depression, and Sleep-Wake Cycle Disorder". Frontiers in Pharmacology 13. 2022. doi:10.3389/fphar.2022.861094. PMID 35721194. 
  3. ↑ 3.0 3.1 "From past to future: 50 years of pharmacological interventions to treat narcolepsy". Pharmacology, Biochemistry, and Behavior 241. August 2024. doi:10.1016/j.pbb.2024.173804. PMID 38852786. 
  4. ↑ "Hits and misses with animal models of narcolepsy and the implications for drug discovery". Expert Opinion on Drug Discovery 19 (6): 755–768. June 2024. doi:10.1080/17460441.2024.2354293. PMID 38747534. 
  5. ↑ "Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses". Clinical Drug Investigation 40 (7): 603–615. July 2020. doi:10.1007/s40261-020-00920-8. PMID 32399853. 

Template:Wakefulness-promoting agents




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Samelisant&oldid=4243675"